一品紅(300723.SZ):陝國投●弘盛26號證券投資集合資金信託計劃買入一品轉債150萬張
格隆匯2月25日丨一品紅(300723.SZ)公佈,公司創業板向不特定對象發行可轉換公司債券事項經中國證監會“證監許可[2020]3316號”文同意註冊,公司於2021年1月28日向不特定對象發行了480萬張可轉換公司債券,每張面值100元,發行總額4.8億元。經深交所同意,公司可轉換公司債券已於2021年2月23日起在深交所掛牌交易,債券簡稱“一品轉債”,債券代碼“123098”。
2月25日,公司收到陝西省國際信託股份有限公司通知,其作為受託人發起設立的陝國投●弘盛26號證券投資集合資金信託計劃近日通過大宗交易方式買入一品轉債150萬張,佔發行總量的31.25%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.